Literature DB >> 23624778

Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.

Alaa T Alshareeda1, Ola H Negm, Nada Albarakati, Andrew R Green, Christopher Nolan, Rebeka Sultana, Srinivasan Madhusudan, Ahmed Benhasouna, Paddy Tighe, Ian O Ellis, Emad A Rakha.   

Abstract

Although the role of BRCA1 and the homologous recombination (HR) pathway in breast cancer (BC) has been extensively studied, the alternative repair pathway for DNA double-strand breaks (DSBs), non-homologous end-joining (NHEJ) remains to be defined. Ku proteins bind to DNA DSB ends and play a key role in NHEJ. In this study we aimed to assess the expression and biological significance of the KU70/KU80 heterodimer in the different molecular classes of BC. The expression of KU70/KU80 was assessed immunohistochemically in a well-characterised and annotated series of 1302 unselected invasive BC cases with a long-term follow-up together with 25 cases with known BRCA1 mutations. The results were correlated with clinicopathological parameters, other DNA repair proteins and patient outcome. The expression of KU70/KU80 protein was further evaluated in various BC cell lines using western blotting and reverse-phase protein microarray (RPPA). Nuclear KU70/KU80 expression was correlated with features of poor prognosis including higher histological grade, lymphovascular invasion, negative oestrogen receptor expression, basal-like phenotype, P53 and CHK1 positivity. KU70/KU80 was expressed in all BRCA1-associated tumours and showed an inverse correlation with nuclear BRCA1 protein and aberrant cytoplasmic RAD51 expression. RPPA confirmed these results and showed higher expression of KU70/KU80 in BRCA1-deficient cell line compared to BRCA1-proficient cell line. KU70/KU80 expression showed an association with disease-free interval; however, it was not an independent predictor of outcome. As a conclusion, KU70/KU80 may play a role in DNA DSBs repair in HR-deficient tumours. Further study of other NHEJ markers in sporadic BC is warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624778     DOI: 10.1007/s10549-013-2542-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Shuai Wang; Zhou Wang; Xiangyan Liu; Yu Yang; Mo Shi; Zhenguo Sun
Journal:  Tumour Biol       Date:  2015-03-11

2.  Overexpression of Ku80 suggests poor prognosis of locally advanced esophageal squamous cell carcinoma patients.

Authors:  Shuai Wang; Zhou Wang; Xiangyan Liu; Yu Liu; Yang Jia
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

3.  7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells.

Authors:  Dermot O'Sullivan; Michael Henry; Helena Joyce; Naomi Walsh; Edel Mc Auley; Paul Dowling; Niall Swan; Michael Moriarty; Paul Barnham; Martin Clynes; Annemarie Larkin
Journal:  Tumour Biol       Date:  2014-04-18

Review 4.  DNA damage repair functions and targeted treatment in breast cancer.

Authors:  Chenfeng He; Kosuke Kawaguchi; Masakazu Toi
Journal:  Breast Cancer       Date:  2020-01-02       Impact factor: 4.239

5.  Abnormal DNA-PKcs and Ku 70/80 expression may promote malignant pathological processes in gastric carcinoma.

Authors:  Wei Li; Chuan Xie; Zhen Yang; Jiang Chen; Nong-Hua Lu
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

6.  Genetic association of XRCC5 gene polymorphisms with breast cancer among Jordanian women.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Mansour A Alghamdi; Rame H Khasawneh
Journal:  Onco Targets Ther       Date:  2019-09-26       Impact factor: 4.147

7.  KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Authors:  A T Alshareeda; O H Negm; A R Green; C C Nolan; P Tighe; N Albarakati; R Sultana; S Madhusudan; I O Ellis; E A Rakha
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

8.  Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.

Authors:  M M Al-Kaabi; A T Alshareeda; D A Jerjees; A A Muftah; A R Green; N H Alsubhi; C C Nolan; S Chan; E Cornford; S Madhusudan; I O Ellis; E A Rakha
Journal:  Br J Cancer       Date:  2015-02-17       Impact factor: 7.640

9.  DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Authors:  Mohammed Aleskandarany; Daniela Caracappa; Christopher C Nolan; R Douglas Macmillan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res Treat       Date:  2015-02-19       Impact factor: 4.872

10.  Selective Targeting to Glioma with Nucleic Acid Aptamers.

Authors:  Shraddha Aptekar; Mohit Arora; Clare Louise Lawrence; Robert William Lea; Katherine Ashton; Tim Dawson; Jane Elizabeth Alder; Lisa Shaw
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.